Ropeg superior to phlebotomy alone in maintaining hematocrit control in polycythemia vera

Italy: Exposure to low-dose ropeginterferon alfa-2b (ropeg) is more effective than the standard treatment of phlebotomy and aspirin in patients with low-risk polycythemia vera (PV), a 24-month trial...

Related Keywords

Italy , Tiziano Barbui , , Standard Therapy , Low Risk Patients , Nejm Evidence , Ropeginterferon , Phlebotomy , Polycythemia Vera , Aspirin , Hematocrit ,